Vodafone's growth improves in first quarter
The mobile operator also said on Thursday it was reiterating its full year guidance of growth in profit and cash flow.
Chief Executive Margherita Della Valle has reshaped the British group in the last two years by selling operations in Spain and Italy and merging its UK operations with those of CK Hutchison to create "VodafoneThree".
Analysts have applauded Della Valle's actions, which have reduced debt and sharpened Vodafone's operational performance. Its shares are up 22% so far this year.
"After two years of transformation and change, Vodafone is now well positioned for multi-year growth across both Europe and Africa," Della Valle said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
BT, EE and Plusnet announce new price rises
BT and EE have raised mid-contract price rises for customers taking out a new deal from Thursday. New BT and EE customers who sign up for broadband from July 31 will see their monthly price rise by £4 mid-way through their contract. This will come into effect on March 31 next year, then again on the same date in 2027. The previous mid-contract price rise was £3 a month. Meanwhile, Plusnet customers will also be subject to a mid-contract price rise of £4 a month from August 5. EE, BT and Plusnet mobile customers will also be hit with higher mid-contract price rises. Those who are a Sim-only or Flex Pay customer will see their contract price rise by £2.50 a month from April, while bundled handset and airtime plan customers will face a £4 rise. A BT consumer spokesman said: 'We are very supportive of Ofcom's requirement to show upfront pounds and pence charges. EE was the first provider to introduce this pricing model, offering EE customers a predictable long-term view of their contract terms. Our pricing approach is designed to be clear for our customers. 'We continue to invest in our business, building on 11 years as the best network to better serve our customers with a reliable and quality connection as we roll out the fastest speed technology to 30 million homes by the end of the decade. We're focused on providing value and customer satisfaction, making new technologies available to our customers such as 5G standalone and WiFi 7.' Ernest Doku, telecoms spokesman at said: 'In another pounding for consumers' wallets, BT, EE and Plusnet will hike mid-contract price rises to £4 per month for broadband and EE £2.50 per month for some mobile customers. 'This adds an extra £1 to mid-contract price rises for new and recontracting customers signing up from 31 July 2025 for EE and BT and 5 August 2025 for Plusnet. 'BT's price updates have often set a precedent for other providers to follow suit. If this trend continues, the telecoms industry runs the risk of creating its own, accelerated rate of inflation.' Mr Doku added: 'Based on our research, where the average BT customer pays £31.50, EE customer £29.20 and Plusnet customer £25.80 for home broadband, this represents a staggering rise of between 12.6% and 15.5% – significantly higher than current inflation of 3.6%. 'From 31 July, EE Sim-only and Flex Pay airtime mobile customers signing up for new deals will see a £2.50 monthly increase applied in March 2025. For those taking out EE's cheapest £18 per month Sim-only plan, this is the equivalent of a notable 13.8% hike. 'This change only applies to customers taking out new contracts, so if you are currently a BT, Plusnet or EE customer and your plan is up for renewal before March 2026 you should shop around for other options. Many regional broadband providers such as YouFibre and Trooli and mobile providers including Lebara and Smarty don't raise prices mid-contract.' Which? director of policy and advocacy Rocio Concha said: 'It's shocking that BT is choosing to increase its mid-contract price rises above the rate of inflation for any new customers who sign up for broadband packages from BT, EE or Plusnet from 31st July. 'Any out-of-contract BT, EE and Plusnet customers who aren't happy with these hikes should vote with their feet and switch to a cheaper deal. 'We'd always recommend carefully weighing up the total costs of any new contract to ensure it offers value for money and you're aware of any possible increases.'
Yahoo
22 minutes ago
- Yahoo
Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health
Discover insights with the "Glaucoma - Global Clinical Trials Review, 2025." This comprehensive report outlines the global scenario of glaucoma clinical trials, offering top-line data by region, country, phase, and sponsor type. Leverage key findings to enhance decision-making and optimize strategies in the competitive clinical trials landscape. Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Glaucoma - Global Clinical Trials Review, 2025" has been added to offering. The clinical trial report offers a comprehensive overview of the global landscape for Glaucoma clinical trials. This detailed analysis provides key insights into trial numbers and average enrollment rates across leading nations. The report encompasses a thorough coverage of clinical trials by region, country (G7 & E7), phase, trial status, endpoint status, and sponsor type. Additionally, it highlights prominent drugs currently undergoing trials, based on the number of ongoing studies. The analyst Clinical Trial Reports are meticulously compiled using the proprietary Pharma - Clinical Trials Database. Data is aggregated from over 80 clinical trial registries, conferences, journals, and news sources worldwide, and the database is updated dynamically to reflect the latest information. The report significantly enhances decision-making capabilities, empowering stakeholders to craft effective counterstrategies and secure a competitive edge. It should be noted that certain sections of the report may undergo modifications based on data availability and relevance. Scope Provides a snapshot of the global clinical trials landscape. Includes top-level data related to clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status. Reviews key companies involved and lists all trials (title, phase, and status) associated with each company. Details unaccomplished trials (terminated, suspended, or withdrawn) with reasons for non-completion. Discusses enrollment trends from the past five years. Offers the latest industry news from the past three months. Reasons to Buy Facilitates the development of strategic business initiatives related to investment. Identifies optimal locations for conducting clinical trials, maximizing efficiency and cost-effectiveness. Provides top-level analysis of the Global Clinical Trials Market, aiding in the discovery of key business opportunities. Enhances understanding of trial counts and enrollment trends by country in the global therapeutics market. Enables interpretation of clinical trial success rates by presenting comparative scenarios of completed and uncompleted trials. Supports clinical trial assessment for indications at global, regional, and country levels. Key Topics Covered: Report Guidance The analyst Clinical Trials Report Coverage Clinical Trials by Region Clinical Trials by G7 Countries Proportion of Glaucoma to Ophthalmology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by E7 Countries Proportion of Glaucoma to Ophthalmology Clinical Trials Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Phase Clinical Trials by Trial Status Clinical Trials by Sponsor Type Prominent Sponsors Prominent Drugs Latest Clinical Trials News on Glaucoma Jun 24, 2025: Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients May 07, 2025: Galimedix Therapeutics completes SAD portion of Phase I trial of oral GAL-101 May 05, 2025: Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy Apr 24, 2025: Stealth Biotherapeutics To Present New Bevemipretide Data at ARVO Annual Meeting Clinical Trial Profile Snapshots A selection of companies mentioned in this report includes, but is not limited to: Alcon Inc AbbVie Inc Santen Pharmaceutical Co Ltd Pfizer Inc Kowa Co Ltd Viatris Inc Merck & Co Inc Novartis AG Senju Pharmaceutical Co Ltd Bausch Health Companies Inc For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Insider information: Kojamo lowers its outlook for 2025 due to the sales of residential properties
HELSINKI, July 31, 2025 /PRNewswire/ -- Kojamo plc Insider information, 31 July 2025 at 12:05 p.m. EEST Kojamo lowers its outlook for 2025 for total revenue and specifies for Funds From Operations (FFO). Background for the outlook change Kojamo has completed the sale of 44 rental housing properties which covers 1,944 apartments from eight different municipalities across Finland. The completion of the sales was announced earlier today. The transaction is estimated to decrease Kojamo's total revenue in 2025 by approximately EUR 9.2 million and FFO by approximately EUR 2.9 million. The sale price is approximately 10 per cent below the balance sheet value for 2024. The company estimates that the transaction does not have an impact on the fair values of the remaining investment properties. The impact on the occupancy rate is estimated to be marginal. The transaction will result in approximately EUR 25 million in taxes, payable in January 2026. The sale of these non-strategic properties is aligned with Kojamo's goals for the current year. New outlook for 2025 Kojamo estimates that in 2025, the Group's total revenue will increase by 0-2 per cent year-on-year. In addition, Kojamo estimates that the Group's FFO for 2025 will amount to between EUR 135-141 million, excluding non-recurring costs. The outlook takes into account the estimated occupancy rate and development of rents. The total revenue and FFO outlook also takes into account the impacts of disposal of the 44 residential properties, but it does not take into account the impact of potential future acquisitions or disposals. The outlook does not take into account the taxes resulting from the transaction. Previous outlook for 2025 (according to the Kojamo plc's Interim report 1 January - 31 March 2025) Kojamo estimates that in 2025, the Group's total revenue will increase by 1-4 per cent year-on-year. In addition, Kojamo estimates that the Group's FFO for 2025 will amount to between EUR 135-145 million, excluding non-recurring costs. The outlook takes into account the estimated occupancy rate and development of rents. The outlook does not take into account the impact of potential acquisitions or disposals on total revenue and FFO. For more information, please contact: Reima Rytsölä, CEO, Kojamo plc, tel. +358 20 508 5077, Erik Hjelt, CFO, Kojamo plc, tel. +358 20 508 3225, Distribution: Nasdaq Helsinki, key media Kojamo is Finland's largest private residential real estate company and one of the biggest investors in Finland. Our mission is to create better urban housing. Lumo offers environmentally friendly housing and services for the city dweller who appreciates quality and effortlessness. We actively develop the value of our investment properties by developing new properties and our existing property portfolio. We want to be the property market frontrunner and the number one choice for our customers. Kojamo's shares are listed on the official list of Nasdaq Helsinki. For more information, please visit This information was brought to you by Cision View original content: Sign in to access your portfolio
